Drugs remained approximately 10% of medical costs, with physician-dispensed drugs accounting for 5% of total drug payments.
Drugs remained approximately 10% of medical costs, with physician-dispensed drugs accounting for 5% of total drug payments.
Spending remains high despite limits passed in 2025, with patterns of duplicate therapy, lack of medical necessity, and changes in drug strength.
To support early clinical trials for the psychedelic, the FDA is asking for information on study design, dosing, safety considerations, and more.
Topics included ODG updates, rulemaking activity, AMA Guides, mental health claim trends, and utilization review enforcement.
Key conversations focused on access to care, emerging technologies, GLP-1s, and topical analgesics.
The November 3rd meeting will provide the public a chance to comment on fee schedule rules and other regulations.
As part of the proposal, the state has issued a stakeholder survey that will close October 22nd.
A workshop to streamline workers’ comp regulations will now take place October 12th.
Agenda topics include topicals, GLP-1 drugs, biologics, PPI and H2 blockers, and more.
The proposal would incorporate the latest ACOEM Guideline for knee disorders, and a public hearing is scheduled for October 16th.
The meeting will take place September 24th, with agenda topics including provision of coverage, benefits for injury or death, and occupational diseases.
Stakeholders can submit feedback on the research agenda through September 28th.
The proposed changes will have a 45-day public comment period for stakeholders to provide feedback.
Impacted drugs include physician-dispensed and repackaged drugs, topicals, compounds, and OTC medications.
Impacted items would include pharmacy and topical reimbursement, home health, prior authorization, and more.
